Transdermal opioids for cancer pain

Current Opinion in Supportive and Palliative Care

Volumn 5, Issue 1, 2011, Pages 15-19

  Cachia, Elaine ^a   Ahmedzai, Sam H ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Buprenorphine; Cancer pain; Fentanyl; Transdermal opioids

Indexed keywords

BUPRENORPHINE; FENTANYL; NARCOTIC ANALGESIC AGENT;

ARTICLE; EVIDENCE BASED MEDICINE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; NEOPLASM; PAIN;

ADMINISTRATION, CUTANEOUS; ANALGESICS, OPIOID; BUPRENORPHINE; EVIDENCE-BASED MEDICINE; FENTANYL; HUMANS; NEOPLASMS; PAIN;

EID: 79954542808     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e3283437a39     Document Type: Article

References (31)

1. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330:592-596. (Pubitemid 24065792)
2. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18:1437-1449. One of the most comprehensive systematic reviews of the epidemiology of cancer pain at all stages of the disease. (Pubitemid 47365475)
3. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84:587-593. (Pubitemid 32238990)
4. Margetts LSR. Transdermal drug delivery: principles and opioid therapy. Contin Educ Anaesth Crit Care Pain 2007; 7:171-176.
5. Benson HA. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv 2005; 2:23-33. (Pubitemid 40590918)
6. Payne R, Chandler S, Einhaus M. Guidelines for the clinical use of transdermal fentanyl. Anticancer Drugs 1995; 6 (Suppl 3):50-53.
7. Zeppetella G, Wiffen PJ. Buprenorphine for cancer pain (Protocol). Cochrane Database Syst Rev. 2007:CD006766.
8. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005; 29:297-326. (Pubitemid 40386746)
9. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009; 13:219-230. An up to date review on the evidence around the use of buprenorphine patches.
10. Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 2000; 21:1141-1146.
11. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006; 96:627-632.
12. Terlinden R ST, editor. Pharmacokinetic study on single application of buprenorphine transdermal system (TDS). Pain in Europe III, 2000: advances in Pain Research and Therapy; 2000; Nice, France.
13. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 2003; 63:1999-2010; discussion 1-2. (Pubitemid 37222571)
14. Likar R, Kayser H, Sittl R. Results of an open-label, multicentre, follow-up study. Transdermal buprenorphine for long-term management of chronic cancer and noncancer pain. Book of Abstracts, International Forum on Pain Medicine; Bulgaria; 2005.
15. Hans GRD. Transdermal buprenorphine: a critical appraisal of its role in pain management. J Pain Res 2009; 2:117-134.
16. Filitz J, Griessinger N, Sittl R, et al. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with trans dermalbuprenorphine.Eur JPain2006;10:743-748.
17. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, doubleblind, placebo-controlled trial. Clin Ther 2003; 25:150-168. (Pubitemid 36206743)
18. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004; 26:1808-1820. (Pubitemid 40089494)
19. Böhme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS) in the treatment of patients with chronic pain. A randomized, double-blind, placebo-controlled study. Pain Clinic 2003; 15:193-202. (Pubitemid 36644341)
20. Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther 2006; 28:943-952. (Pubitemid 44062699)
21. Pace MC, Passavanti MB, Grella E, et al. Buprenorphine in long-term control of chronic pain in cancer patients. Front Biosci 2007; 12:1291-1299. (Pubitemid 46846834)
22. Deandrea S, Corli O, Moschetti I, Apolone G. Managing severe cancer pain: the role of transdermal buprenorphine: a systematic review. Ther Clin Risk Manag 2009; 5:707-718. A comprehensive and critical review of the evidence on buprenorphine patches used in cancer pain management: it shows the heterogeneity of published work and the lack of conclusive evidence so far.
23. Freynhagen R, von Giesen HJ, Busche P, et al. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain. J Pain Symptom Manage 2005; 30:289-297. (Pubitemid 41354935)
24. Prommer E. The role of fentanyl in cancer-related pain. J Palliat Med 2009; 12:947-954.
25. Kress HG, Von der Laage D, Hoerauf KH, et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom Manage 2008; 36:268-279.
26. Heiskanen T, Matzke S, Haakana S, et al. Transdermal fentanyl in cachectic cancer patients. Pain 2009; 144:218-222. An interesting paper that highlights the common scenario of cancer cachexia and how that may affect pain management using patch technology.
27. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997; 13:254-261. (Pubitemid 27240678)
28. Clark AJ, Ahmedzai SH, Allan LG, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic noncancer pain. Curr Med Res Opin 2004; 20:1419-1428. (Pubitemid 39361345)
29. Tassinari D, Sartori S, Tamburini E, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 2008; 11:492-501. The most recent and comprehensive systematic review and meta-analysis of both fentanyl and buprenorphine patches used in trials of cancer pain. (Pubitemid 351440551)
30. Tassinari D, Sartori S, Tamburini E, et al. Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Palliat Care 2009; 25:172-180. A detailed review of the evidence on transdermal fentanyl and its place in the management of cancer pain.
31. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008; 35:214-228.